Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk. Issue 12 (28th August 2018)

• Record Type: Journal Article
• Authors: Darvishian, Maryam; Janjua, Naveed Z.; Chong, Mei; Cook, Darrel; Samji, Hasina; Butt, Zahid A.; Yu, Amanda; Alvarez, Maria; Yoshida, Eric; Ramji, Alnoor; Wong, Jason; Woods, Ryan; Tyndall, Mark; Krajden, Mel
• Is Part Of: Journal of viral hepatitis. Volume 25:Issue 12(2018)
• Page Start: 1481
• Page End: 1492
• Publication Date: 2018-08-28
• Subjects: BC hepatitis testers cohort -- Canada -- hepatitis C virus -- hepatocellular carcinoma -- population attributable fraction -- proportional hazard models; Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.12977
• Languages: English
• ISSNs: 1352-0504

Abstract

Summary: Although achieving sustained virological response (SVR) through antiviral therapy could reduce the risk of hepatocellular carcinoma (HCC) attributable to hepatitis C virus (HCV) infection, the impact of early viral clearance on HCC is not well defined. In this study, we compared the risk of HCC among individuals who spontaneously cleared HCV (SC), the referent population, with the risk in untreated chronic HCV (UCHC), those achieved SVR, and those who failed interferon‐based treatment (TF). The BC Hepatitis Testers Cohort (BC‐HTC) includes individuals tested for HCV between 1990‐2013, integrated with medical visits, hospitalizations, cancers, prescription drugs and mortality data. This analysis included all HCV‐positive patients with at least one valid HCV RNA by PCR on or after HCV diagnosis. Of 46 666 HCV‐infected individuals, there were 12 527 (26.8%) SC; 24 794 (53.1%) UCHC; 5355 (11.5%) SVR and 3990 (8.5%) TF. HCC incidence was lowest (0.3/1000 person‐years (PY)) in the SC group and highest in the TF group (7.7/1000 PY). In a multivariable model, compared to SC, TF had the highest HCC risk (hazard ratio (HR):14.52, 95% confidence interval (CI): 9.83‐21.47), followed by UCHC (HR: 5.85; 95% CI: 4.07‐8.41). Earlier treatment‐based viral clearance similar to SC could decrease HCC incidence by 69.4% (95% CI: 57.5‐78.0), 30% (95% CI: 10.8‐45.1) and 77.5% (95% CI: 69.4‐83.5) among UCHC, SVR and TF patients, respectively. In conclusion, using SC as a real‐world comparator group, it showed that substantial reduction in HCC risk could be achieved with earlier treatment initiation. These analyses should be replicated in patients who have been treated with direct acting antiviral therapies.